Blood Work While on Keppra (Levetiracetam)
Routine laboratory monitoring is generally not required for patients on levetiracetam (Keppra), as this medication does not necessitate systematic blood work for therapeutic drug monitoring or organ function surveillance in most clinical situations.
Baseline Laboratory Testing
According to the FDA drug label, minimal baseline testing is recommended 1:
- Complete Blood Count (CBC): Obtain at baseline to establish a reference point
- Liver Function Tests (LFTs): Obtain at baseline for comparison if issues arise
The FDA label specifically notes that "there were no meaningful changes in mean liver function tests in controlled trials" and that "lesser LFT abnormalities were similar in drug and placebo treated patients" 1.
Routine Monitoring During Treatment
No routine periodic blood work is required for the majority of patients on levetiracetam. This represents a significant advantage over older antiepileptic drugs 1.
Hematologic Considerations
While the FDA label documents minor decreases in blood counts, these changes are typically not clinically significant 1:
- Adults: Small decreases in RBC count (0.03 x 10⁶/mm³), hemoglobin (0.09 g/dL), and hematocrit (0.38%) were seen
- Only 3.2% of treated patients had potentially significant WBC decreases (≤2.8 x 10⁹/L)
- Only 2.4% had potentially significant neutrophil decreases (≤1.0 x 10⁹/L)
- Importantly: No patients were discontinued due to low blood counts 1
Hepatic Considerations
The FDA label confirms that hepatotoxicity is rare with levetiracetam 1:
- Only 1 patient (0.07%) was discontinued from controlled trials for LFT abnormalities
- LFT abnormalities occurred at similar rates in drug and placebo groups (1.4%)
Special Populations Requiring Monitoring
1. Renal Impairment
Monitor renal function (serum creatinine, estimated GFR) if:
- Baseline renal disease exists
- Patient is elderly (increased risk of renal dysfunction)
- Critically ill patients, particularly those with augmented renal clearance 2
Rationale: Levetiracetam is 66% renally eliminated, and dose adjustments are necessary when creatinine clearance falls below certain thresholds 3.
2. Critically Ill Patients
Consider therapeutic drug monitoring (TDM) in ICU settings 3, 2:
- Augmented renal clearance may require higher doses
- Standard doses may result in subtherapeutic levels
- Target therapeutic range: 20-40 mg/L (though correlation with efficacy is not firmly established)
3. Pediatric Patients
- Baseline CBC recommended
- No routine monitoring unless clinical concerns arise
- Clearance is 30-40% higher than adults, but routine TDM is not indicated 3
4. Elderly Patients (>65 years)
- Baseline renal function assessment
- Periodic renal function monitoring (every 6-12 months) given age-related decline in clearance 3
- Clearance decreased by almost 50% compared to younger adults
5. Pregnant Patients
- No specific blood work required for levetiracetam monitoring
- Standard prenatal care applies
- Consider TDM if seizure control deteriorates, as clearance increases during pregnancy 3
When to Consider Therapeutic Drug Monitoring
TDM is NOT routinely recommended but may be useful in specific scenarios 3, 4, 5:
- Suspected non-compliance: To verify medication adherence
- Breakthrough seizures: To determine if levels are subtherapeutic
- Renal dysfunction: To guide dose adjustments
- Critical illness: When pharmacokinetics may be significantly altered
- Drug interactions: When enzyme-inducing AEDs are co-administered (22% increase in clearance) 1
Important caveat: Multiple studies show no clear correlation between levetiracetam levels and either efficacy or toxicity 3, 4, 5. The therapeutic range of 20-40 mg/L is not firmly established, and seizure control has been achieved at levels both below and above this range.
Clinical Monitoring (Non-Laboratory)
Focus clinical monitoring on:
- Neuropsychiatric symptoms: Behavioral changes, mood disturbances, suicidal ideation (most important safety concern) 1
- Somnolence and dizziness: Most common adverse effects 6
- Seizure frequency: Clinical efficacy assessment
Key Pitfalls to Avoid
- Do not order routine monthly labs: This is unnecessary and not supported by evidence
- Do not assume therapeutic drug monitoring is needed: Unlike phenytoin or valproate, levetiracetam has predictable pharmacokinetics and minimal drug interactions 1
- Do not ignore renal function in elderly patients: This is the one population where periodic monitoring is justified
- Do not rely solely on drug levels for dose adjustments: Clinical response is more important than achieving a specific level 4, 5